NO.889 P.2

Docket No: LD262NF

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being glached or enclosed) is being faceimile transmitted to the Faten Trademark Office on the date shown below.

Maureen S. Gibbons

Type or print name

May 28, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit:

1614

Ajani, et al.

Examiner:

Frederick F. Krass

APPLICATION NO: 10/090,354

FILED:

March 4, 2002

FOR: METHOD AND DOSAGE FORM FOR TREATING TUMORS BY THE

ADMINISTRATION OF TEGAFUR, URACIL, FOLINIC ACID,

PACLITAXEL AND CARBOPLATIN

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

In response to the Office Action mailed on February 28, 2003, in connection with the above-identified application, Applicants respectfully request reconsideration based upon the following remarks,

REMARKS

Claims 1 to 13 are pending. Claims 1 to 11 and 13 stand rejected under 35 U.S.C. 112, ¶1 for an alleged lack of enablement. Claims 1-5, 8 and 13 stand rejected under 35 U.S.C. 103(a) as allegedly unpatentable over Bissery (USP 6,239,167) in view of Junji et al. (USP 5,534513).

35 U.S.C. 112 ¶1

The present claims are directed to methods for treating cancer using a combination of tegafur, uracil, folinic acid, paclitaxel and carboplatin. Applicants have found that the claimed combination is useful for treating a variety of tumors. Applicants agree that the mechanisms by which anticancer drugs work are not always well